TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bladder cancer called intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC).
- Your tumor has a specific change in the FGFR gene (a mutation or fusion).
- All visible tumors have been fully removed by surgery before the study starts.
- You are willing to have regular bladder exams (cystoscopies) and possibly more surgery if the cancer returns.
- You are healthy enough to have a performance status of 0 to 2 (means you can do daily activities with little help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
This study looks at how patients with non-muscle invasive bladder cancer are using TAR-200 in everyday medical care. It aims to understand treatment patterns and outcomes outside of a clinical trial.
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This study compares a new combination of chemotherapy drugs delivered directly into the bladder versus standard treatment for people with non-muscle invasive bladder cancer that has returned or not responded to prior therapy. It aims to see if the new treatment helps prevent the cancer from coming back.
Hear when a new Non-Muscle Invasive Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.